STAT+：礼来公司的GLP-1口服药Foundayo在研究中有助于缓解睡眠呼吸暂停
摘要
礼来公司的GLP-1口服药Foundayo在两项后期研究中有助于缓解睡眠呼吸暂停，但其效果似乎不及礼来的注射药物Zepbound。在一项为期一年、针对未接受PAP治疗（一种通气方式）患者的试验中，服用Foundayo的患者在呼吸暂停低通气指数（AHI）上每小时减少17.8个“事件”，AHI是衡量睡眠中呼吸停止和受限次数的指标。相比之下，安慰剂组患者减少了4.5个事件。此外，根据周一在美国心脏协会年会上公布并发表于《JAMA》的数据，28%的治疗组患者达到缓解或轻度疾病状态，而安慰剂组为13%。继续阅读STAT+以了解完整报道……
English
Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn’t appear as effective as Lilly’s injectable drug Zepbound. In a one-year trial of patients who weren’t receiving PAP therapy, a form of ventilation, those on Foundayo saw a reduction of 17.8 “events” per hour on the apnea-hypopnea index (AHI), a measure of the number of times breathing stops and becomes restricted while sleeping. That compares with a reduction of 4.5 events among those on placebo. Additionally, 28% of treated patients achieved remission or mild disease, compared with 13% in the placebo group, according to data presented Monday at the annual meeting of the American Heart Association and published in JAMA . Continue to STAT+ to read the full story…